Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with an estimated
median survival time of 3–5 years after diagnosis. This condition occurs primarily in elderly …

Obstructive sleep apnea (OSA) is a highly prevalent disorder that has profound implications
on the outcomes of patients with chronic lung disease. The hallmark of OSA is a collapse of …

Despite the development of pharmacological therapies that are effective in slowing the
progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal …

Idiopathic pulmonary fibrosis (IPF) is an advancing and fatal lung disease with increasing
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …

Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial
pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with a poor
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …

In addition to facilitating healthcare delivery planning, reliable information about prognosis is
essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This …

Many patients with idiopathic pulmonary fibrosis (IPF) complain of chronic refractory cough.
Chronic cough is a distressing and disabling symptom with a major impact on quality of life …

Interstitial lung disease (ILD) is a diverse group of inflammatory and fibrotic lung conditions
causing significant morbidity and mortality. A multitude of factors beyond the lungs influence …